Search - tctmd.com

Displaying 361 - 380 of 392

Sort: Relevancy | Date

Presentation THT 2022

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

Subgroup Analyses of the REDUCE LAP-HF II Study of the Corvia Atrial Shunt

Presenter: Barry Borlaug

February 01, 2022

Presentation THT 2022

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Physiological Rationale and Devices for Interatrial Shunts

Presenter: JoAnn Lindenfeld

February 01, 2022

Presentation THT 2022

The Impact of COVID 19 On the Care of Heart Failure Patients and Heart Failure Trials: Will It Ever End?

Presenter: JoAnn Lindenfeld

February 01, 2022

Presentation THT 2022

How to Improve Diversity in Heart Failure: Patients, Investigators, Trials

Presenter: Alanna Morris

February 01, 2022

Presentation THT 2022

Special Challenges of Heart Failure Device Trials

Presenter: Gregg Stone

February 01, 2022

Presentation THT 2022

What’s to Come? Innovation and Technology in Heart Failure

Presenter: Nir Uriel

February 01, 2022

Presentation THT 2022

Key Note Address: When Pigs Fly, How Will Drugs, Devices, and Technologies Enhance the Care of Heart Failure Patients?

Presenter: Douglas Mann

February 01, 2022

Presentation THT 2022

Welcome to "Technologies for Heart Failure Therapeutics"

Presenter: Daniel Burkhoff

February 01, 2022

Presentation THT 2022

Moderator Led Discussion

Presenter: JoAnn Lindenfeld

February 01, 2022

Presentation THT 2022

Moderator Led Discussion

Presenter: Ulrich Jorde

February 01, 2022

Presentation THT 2022

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Liviu Klein

February 01, 2022

Presentation THT 2022

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Roham Zamanian

February 01, 2022

Presentation THT 2022

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Alanna Morris

February 01, 2022

Presentation THT 2022

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

Presenter: Piotr Ponikowski

February 01, 2022

Presentation THT 2022

Right heart catheterization + Exercise testing – best practices for treatment selection in patients with PH due to Left Heart Disease

Presenter: Ryan Tedford

February 01, 2022

Presentation THT 2022

Timing of Intervention and the fate of the RV

Presenter: Barry Borlaug

February 01, 2022

Advertisement

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Subgroup Analyses of the REDUCE LAP-HF II Study of the Corvia Atrial Shunt

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

Physiological Rationale and Devices for Interatrial Shunts

The Impact of COVID 19 On the Care of Heart Failure Patients and Heart Failure Trials: Will It Ever End?

How to Improve Diversity in Heart Failure: Patients, Investigators, Trials

Special Challenges of Heart Failure Device Trials

What’s to Come? Innovation and Technology in Heart Failure

Key Note Address: When Pigs Fly, How Will Drugs, Devices, and Technologies Enhance the Care of Heart Failure Patients?

Welcome to "Technologies for Heart Failure Therapeutics"

Moderator Led Discussion

Moderator Led Discussion

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

Right heart catheterization + Exercise testing – best practices for treatment selection in patients with PH due to Left Heart Disease

Timing of Intervention and the fate of the RV

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content